Coherus Oncology (CHRS) Gains from Investment Securities (2016 - 2025)
Historic Gains from Investment Securities for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $19000.0.
- Coherus Oncology's Gains from Investment Securities fell 9392.97% to $19000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $339000.0, marking a year-over-year decrease of 8099.78%. This contributed to the annual value of $28.7 million for FY2024, which is 2132.73% up from last year.
- Latest data reveals that Coherus Oncology reported Gains from Investment Securities of $19000.0 as of Q3 2025, which was down 9392.97% from $43000.0 recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Gains from Investment Securities registered a high of $2.8 million during Q1 2023, and its lowest value of $10000.0 during Q4 2024.
- In the last 5 years, Coherus Oncology's Gains from Investment Securities had a median value of $326000.0 in 2023 and averaged $687705.9.
- Per our database at Business Quant, Coherus Oncology's Gains from Investment Securities surged by 358260.87% in 2022 and then crashed by 9693.25% in 2024.
- Over the past 5 years, Coherus Oncology's Gains from Investment Securities (Quarter) stood at $23000.0 in 2021, then soared by 3582.61% to $847000.0 in 2022, then plummeted by 61.51% to $326000.0 in 2023, then crashed by 96.93% to $10000.0 in 2024, then soared by 90.0% to $19000.0 in 2025.
- Its last three reported values are $19000.0 in Q3 2025, $43000.0 for Q2 2025, and $267000.0 during Q1 2025.